A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis

Journal of the American Society of Nephrology

Volumn 21, Issue 2, 2010, Pages 231-236

  Smith, Jennifer ^a   McDaid, John P ^a   Bhangal, Gurjeet ^a   Chawanasuntorapoj, Ratana ^a,b   Masuda, Esteban S ^c   Cook, H Terence ^a   Pusey, Charles D ^a   Tam, Frederick W K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

^c RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FOSTAMATINIB DISODIUM; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; LIVER ENZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE SYK INHIBITOR; R 788; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CCL2 PROTEIN, RAT; N4 (2,2 DIMETHYL 3 OXO 4H PYRID(1,4)OXAZIN 6 YL) 5 FLUORO N2 (3,4,5 TRIMETHOXYPHENYL) 2,4 PYRIMIDINEDIAMINE; N4-(2,2-DIMETHYL-3-OXO-4H-PYRID(1,4)OXAZIN-6-YL)-5-FLUORO-N2-(3,4,5-TRIMETHOXYPHENYL)-2,4-PYRIMIDINEDIAMINE; OXAZINE DERIVATIVE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; R788 COMPOUND; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DOWN REGULATION; GLOMERULONEPHRITIS; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MACROPHAGE; MESANGIUM CELL; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; TISSUE INJURY; WEIGHT REDUCTION; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HOSPITALIZATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR KYOTO RAT;

ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS; INTERLEUKIN-1BETA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MESANGIAL CELLS; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; RATS; RATS, INBRED WKY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 77949363952     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009030263     Document Type: Article

References (26)

1. Ansell D, Feehally J, Fogarty D, Tomson C, Williams AJ, Warwick G: UK Renal Registry Report 2008, Bristol, UK, UK Renal Registry, 2008, pp 29-31
2. Tam FWK: Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opin Investig Drugs 15: 1353-1369, 2006
3. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD, Cook HT: Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439: 851-855, 2006
4. Tarzi RM, Davies KA, Claassens JW, Verbeek JS, Walport MJ, Cook HT: Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis. Am J Pathol 162: 1677-1683, 2003
5. Kovalenko P, Fujinaka H, Yoshida Y, Kawamura H, Qu Z, El-Shemi AG, Li H, Mat-suki A, Bilim V, Yaoita E, Abo T, Uchiyama M, Yamamoto T: Fc receptor-mediated accumulation of macrophages in crescentic glomeru-lonephritis induced by anti-glomerular basement membrane antibody administration in WKY rats. Int Immunol 16: 625-634, 2004
6. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T: The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutro-phils. Mol Cell Biol 18: 4209-4220, 1998
7. Futterer K, Wong J, Grucza RA, Chan AC, Waksman G: Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 281: 523-537, 1998
8. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E: Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 124: 244-257, 2007
9. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Gross-bard EB, Payan DG, Masuda ES: R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319: 998-1008, 2006
10. Tam FWK, Smith J, Morel D, Karkar AM, Thompson EM, Cook HT, Pusey CD: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 14: 1658-1666, 1999
11. Smith J, Lai PC, Behmoaras J, Roufosse C, Bhangal G, McDaid JP, Aitman T, Tam FW, Pusey CD, Cook HT: Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat. J Am Soc Nephrol 18: 1816-1823, 2007
12. Turner CM, Tam FW, Lai PC, Tarzi RM, Burn-stock G, Pusey CD, Cook HT, Unwin RJ: Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant 22: 386-395, 2007
13. Sheryanna A, Bhangal G, McDaid J, Smith J, Manning A, Foxwell BM, Feldmann M, Cook HT, Pusey CD, Tam FWK: Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glo-merulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol 18: 1167-1179, 2007
14. Lai PC, Smith J, Bhangal G, Chaudhry KA, Chaudhry AN, Keith JC, Jr., Tam FW, Pusey CD, Cook HT: Interleukin-11 reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis. Nephron Exp Nephrol 101: e146-e154, 2005
15. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67: 1812-1820, 2005
16. Lai PC, Cook HT, Smith J, Keith JC, Jr., Pusey CD, Tam FWK: Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats. J Am Soc Nephrol 12: 2310-2320, 2001
17. Tam FWK, Smith J, Agarwal S, Karkar AM, Morel D, Thompson EM, Pusey CD: Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 84: 58-66, 2000
18. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glo-merular basement membrane glomerulone-phritis. Kidney Int 75: 1060-1070, 2009
19. Kulathu Y, Hobeika E, Turchinovich G, Reth M: The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J 27: 1333-1344, 2008
20. Le RD, Lankar D, Yuseff MI, Vascotto F, Yokoz-eki T, Faure-Andre G, Mougneau E, Glaichen-haus N, Manoury B, Bonnerot C, Lennon-Du-menil AM: Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor. Mol Biol Cell 18: 3451-3462, 2007
21. Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL: A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med 186: 1027-1039, 1997
22. Gevrey JC, Isaac BM, Cox D: Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol 175: 3737-3745, 2005
23. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Gross-bard E: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58: 3309-3318, 2008
24. Tsuge T, Suzuki Y, Shimokawa T, Horikoshi S, Okumura K, Ra C, Tomino Y: Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcalpha receptor (CD89) on glomerular mesangial cells. Inflamm Res 52: 428-432, 2003
25. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 58: 1433-1444, 2008
26. Iyoda M, Hudkins KL, Becker-Herman S, Wie-techa TA, Banas MC, Guo S, Meyer-Bahlburg A, Kowalewska J, Liu G, Ziegler SF, Rawlings DJ, Alpers CE: Imatinib suppresses cryoglob-ulinemia and secondary membranoprolifera-tive glomerulonephritis. J Am Soc Nephrol 20: 68-77, 2009